Cargando…

Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma

OBJECTIVE: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). RESULTS: Overall, treatment was well tolerated with no grade toxicity ≥3. Of 71 patients, 66 patients (93%) eventually reached complete respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Hyun, Park, Joong-Won, Kim, Bo Hyun, Kim, Dae Yong, Moon, Sung Ho, Kim, Sang Soo, Lee, Ju Hee, Woo, Sang Myung, Koh, Young-Hwan, Lee, Woo Jin, Kim, Chang-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790519/
https://www.ncbi.nlm.nih.gov/pubmed/29423102
http://dx.doi.org/10.18632/oncotarget.23428
_version_ 1783296461448937472
author Kim, Tae Hyun
Park, Joong-Won
Kim, Bo Hyun
Kim, Dae Yong
Moon, Sung Ho
Kim, Sang Soo
Lee, Ju Hee
Woo, Sang Myung
Koh, Young-Hwan
Lee, Woo Jin
Kim, Chang-Min
author_facet Kim, Tae Hyun
Park, Joong-Won
Kim, Bo Hyun
Kim, Dae Yong
Moon, Sung Ho
Kim, Sang Soo
Lee, Ju Hee
Woo, Sang Myung
Koh, Young-Hwan
Lee, Woo Jin
Kim, Chang-Min
author_sort Kim, Tae Hyun
collection PubMed
description OBJECTIVE: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). RESULTS: Overall, treatment was well tolerated with no grade toxicity ≥3. Of 71 patients, 66 patients (93%) eventually reached complete response (CR) after PBT: 93.9% (62 of 66) of patients who reached CR within 12 months, and the remaining 4 patients (6.1%) reached CR at 12.5, 16.2, 19.1 and 21.7 months, respectively. The three-year local progression-free survival (LPFS), relapse-free survival (RFS) and OS rates were 89.9%, 26.8%, and 74.4%, respectively. Multivariate analysis revealed that the tumour response was an independent prognostic factor for LPFS, RFS, and OS. CONCLUSION: Most CR was achieved within 1 year after PBT and further salvage treatments in PBT field might be postponed up to approximately 18–24 months. Hypofractionated PBT could be good alternative for HCC patients who are unsuitable for surgical or invasive treatments with curative intent. MATERIALS AND METHODS: Seventy-one inoperable or recurrent HCC patients underwent hypofractionated PBT using 66 GyE in 10 fractions. The tumour responses were defined as the maximal tumour response observed during the follow-up period using the modified Response Evaluation Criteria in Solid Tumors criteria.
format Online
Article
Text
id pubmed-5790519
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57905192018-02-08 Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma Kim, Tae Hyun Park, Joong-Won Kim, Bo Hyun Kim, Dae Yong Moon, Sung Ho Kim, Sang Soo Lee, Ju Hee Woo, Sang Myung Koh, Young-Hwan Lee, Woo Jin Kim, Chang-Min Oncotarget Research Paper OBJECTIVE: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). RESULTS: Overall, treatment was well tolerated with no grade toxicity ≥3. Of 71 patients, 66 patients (93%) eventually reached complete response (CR) after PBT: 93.9% (62 of 66) of patients who reached CR within 12 months, and the remaining 4 patients (6.1%) reached CR at 12.5, 16.2, 19.1 and 21.7 months, respectively. The three-year local progression-free survival (LPFS), relapse-free survival (RFS) and OS rates were 89.9%, 26.8%, and 74.4%, respectively. Multivariate analysis revealed that the tumour response was an independent prognostic factor for LPFS, RFS, and OS. CONCLUSION: Most CR was achieved within 1 year after PBT and further salvage treatments in PBT field might be postponed up to approximately 18–24 months. Hypofractionated PBT could be good alternative for HCC patients who are unsuitable for surgical or invasive treatments with curative intent. MATERIALS AND METHODS: Seventy-one inoperable or recurrent HCC patients underwent hypofractionated PBT using 66 GyE in 10 fractions. The tumour responses were defined as the maximal tumour response observed during the follow-up period using the modified Response Evaluation Criteria in Solid Tumors criteria. Impact Journals LLC 2017-12-19 /pmc/articles/PMC5790519/ /pubmed/29423102 http://dx.doi.org/10.18632/oncotarget.23428 Text en Copyright: © 2018 Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Kim, Tae Hyun
Park, Joong-Won
Kim, Bo Hyun
Kim, Dae Yong
Moon, Sung Ho
Kim, Sang Soo
Lee, Ju Hee
Woo, Sang Myung
Koh, Young-Hwan
Lee, Woo Jin
Kim, Chang-Min
Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title_full Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title_fullStr Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title_full_unstemmed Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title_short Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
title_sort optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790519/
https://www.ncbi.nlm.nih.gov/pubmed/29423102
http://dx.doi.org/10.18632/oncotarget.23428
work_keys_str_mv AT kimtaehyun optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT parkjoongwon optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT kimbohyun optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT kimdaeyong optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT moonsungho optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT kimsangsoo optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT leejuhee optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT woosangmyung optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT kohyounghwan optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT leewoojin optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma
AT kimchangmin optimaltimeoftumourresponseevaluationandeffectivenessofhypofractionatedprotonbeamtherapyforinoperableorrecurrenthepatocellularcarcinoma